Let's Get Started

Biotech

Petros Pharma (PTPI) to launch an OTC Erectile dysfunction pill?

Petros Pharma (PTPI) to launch an OTC Erectile dysfunction pill?

Dec 14, 2021

Company Name: Petros Pharmaceuticals, Inc. 

Ticker: (PTPI)

Exchange: NASDAQ

Website: https://STENDRA.com/.

Company Summary:

Petros Pharmaceuticals is committed to the goal of becoming a world-leading specialized men’s health company by identifying, developing, acquiring, and commercializing innovative therapeutics for men’s health issues, including, but not limited to, erectile dysfunction, endothelial dysfunction, psychosexual and psychosocial ailments, Peyronie’s disease, hormone health, and substance use disorders.

Why did it go up over 100%?

Petros Pharmaceuticals, Inc. (“Petros” or “the Company”) (Nasdaq: PTPI), a leading provider of therapeutics for men’s health, today reports positive over-the-counter (OTC) draft label comprehension study results for its erectile dysfunction (ED) Drug STENDRA® (avanafil). This Pivotal Label Comprehension Study was designed to assess comprehension of a draft STENDRA® Drug Facts Label intended for OTC use. This study is a key component in the Company’s plans to engage in discussions with the FDA to expand the product’s access through application for a possible OTC pathway. Early study indicators show positive label comprehension outcomes in the study, which has encouraged the Company to initiate the next step, a Self-Selection Study, as it continues to build the case for the FDA for OTC access to STENDRA.

“The label comprehension study is a key component of our plans to help expand access for STENDRA beyond the prescription model, and to make STENDRA potentially the first prescription-grade ED medication to become available over-the-counter in the United States. While the process of gathering data to be shared with the U.S. Food and Drug Administration (FDA) continues, we are enthusiastic about our progress toward providing new hope for the millions of men suffering from this condition,” commented Fady Boctor, Petros’s President and Chief Commercial Officer.

The first “potentially the first prescription-grade ED medication to become available over-the-counter in the United States.” EVER?!?

I’m a big fan of this company and the recent news it released. Let’s take a look at the chart.

5 Day Technical Analysis:

It’s been gapping up and pulling back for the last 4 days and it looks like it is still bullish but it is possibly about to go bearish! Let’s tak a close look at the 1 day.

1 Day CHart Technical Analysis

It’s very simple, can it beat $4.38? Yes, then I would wait for a pull back and then swing trade it for a quick scalp. If it can’t, I would expect a pullback then consolidation and then a run! Overall, I love the stock because of the news. The first OTC ED med, say what!?!?

read more
TWO STOCKS GO UP 109% in Two Trading Days!

TWO STOCKS GO UP 109% in Two Trading Days!

Dec 7, 2021

Click HERE To Receive Exclusive, PRIVATE-PREMIUM STOCK PICKS & Possibly $250 (Yes we’re bribing you)


Alex predicts QLGN as bullish, GOES UP 98% in 2 trading days, the PROOF is below!

Date Alerted: 11/24/21

Company Name: Qualigen Therapeutics, Inc. 

Website: https://www.qualigeninc.com/

Ticker: QLGN

Forecasted Performance Outlook on 11/24: Bullish

11/24 Alert Price: $1.47

11/29 Alert High: $2.90

Two Trading Day % GAIN: 98%

The PROOF – 11/24 Technical Summary:

On 11/23 we stated, “We think this is a reasonable market reaction to the news, it wasn’t over-purchased, it was just right!” Here is the proof that we said what we said we did. LINK

98% Gains in TWO TRADING DAYS, now that is UNBELIEVABLE!

Take a look at the chart, on 11/24/21 the morning of the alert, the stock blasted off from $6.74 to $2.90

It does sound Unbelievable, here is the PROOF:

On November 24th Alex wrote, “The stock is performing well with strong technicals and fundamentals. We believe in waiting until a strong definitive signal is clear until a decision is made in regards to the future movement of this stock. It’s consolidating and looks like it could still run but until it breaks out of the consolidation trend, trade carefully with stop orders.” Here

PRVB skyrockets 11% in 24 hours, the PROOF is below!

Date Alerted: 11/23/21

Company Name: Provention Bio

Website: www.proventionbio.com

Ticker: PRVB

Forecasted Performance Outlook on 11/23: Bullish

11/23 Alert Price: $6.74

11/24 Alert High: $7.45

One Day % GAIN: 11%

The PROOF – 11/23 Technical Summary:

On 11/23 we stated, “We think this is a reasonable market reaction to the news, it wasn’t over-purchased, it was just right!” Here is the proof that we said what we said we did. LINK

11% Gains in 24 HOURS, now that is GREAT!

Take a look at the chart, on 11/23/21 the morning of the alert, the stock blasted off from $6.74 to $7.45

Click HERE To Receive Exclusive, PRIVATE-PREMIUM STOCK PICKS & Possibly $250 (Yes we’re bribing you)

read more
UPDATE: ISPC Gains 200%, We Called It!

UPDATE: ISPC Gains 200%, We Called It!

Nov 30, 2021

Company Name: iSpecimen

Ticker: ISPC

Exchange: NASDAQ

Website: www.ispecimen.com

Industry  Medical

Company Summary:

iSpecimen offers an online marketplace for human biospecimens, connecting life scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. 

Why is it so Bullish?

iSpecimen announced 8 days ago that it has been contracted to support new advanced research on COVID-19 seeking insights on its transmissibility, variants, outcomes, and testing validity among multiple population segments. In the last ten months, the company has partnered with multiple research and health care organizations on a range of diverse projects requiring a variety of COVID-19 samples, including nasal swabs, saliva, and blood products. 

On Nov. 29, 2021 ISPC entered into a definitive securities purchase agreement for a private placement with three accredited investors for the sale of 1,749,999 shares of common stock of iSpecimen together with warrants to purchase 1,312,500 shares of common stock (“Warrants”), which will result in gross proceeds to iSpecimen of approximately $21.0 million, before deducting placement offering expenses.

UPDATE: BELOW is the article written on November 22nd 

Small Cap wisely assessed the situation by writing, 

“It broke out of the bullish trend at the end of the day, but it could be a head fake. Be careful and make sure to get a solid confirmation before thinking about this purchase.”

WE NAILED IT! The stock went up another 200% after we alerted and it was and always will be about being calculated, not being emotional and reading charts with a technical eye. Always wait for confirmation is the learning lesson!

1 Day Chart 

5 Day

Technical Summary

We are in the same boat as last time, we are in a bearish moment on the 1 day but overall still bullish. This stock is volatile right now and be very careful, it is up 300% of late and is overbought. Wait for confirmations and there is a lot of money to be made on the up and coming swings, both positive and negative movements.

read more
3 Momentum Stocks: Avenue Therapeutics (ATXI), Pasithea Therapeutics (KTTA), Biofrontera (BFRI)

3 Momentum Stocks: Avenue Therapeutics (ATXI), Pasithea Therapeutics (KTTA), Biofrontera (BFRI)

Nov 30, 2021

There are plenty of stocks that have managed to perform strongly over the course of the past week or so and it is perhaps a good time for investors to take a look at some of those. Here is a look at three of those stocks which have managed to record significant gains in that period.

1 Avenue Therapeutics (NASDAQ:ATXI)

The first one to look into this week is the Avenue Therapeutics Inc stock, which has managed to emerge as one of the biggest gainers in the market over the course of the past week. Yesterday, the stock was in sharp focus among investors and ended the day with gains of as much as 53% as a consequence. The company is mainly involved in the development of intravenous tramadol that is meant for the United States market.

Yesterday, the company got a major boost after Avenue announced that it had been informed by the United States Food and Drug Administration that a meeting is going to take place on February 22, 2022, between the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee.

At the meeting, the New Drug Application submitted by Avenue is going to be discussed by the committees. It is quite clear to see that it is a significant development for the company and hence, the market reacted positively to the news. At this point in time, it might be a good idea to keep the Avenue Therapeutics stock in your watch lists and keep an eye on the developments in the lead-up to February 15 next year.

2 Pasithea Therapeutics (NASDAQ:KTTA)

One of the stocks to have captured the imagination of investors in the past week is that of Pasithea Therapeutics. The stock has had a rollicking run over the course of the past week and managed to clock gains of as much as 80% during the period. There was no news about the company yesterday but the rally actually started in the stock last week after it emerged on November 22 that Pasithea had added its esketamine nasal spray to the range of offerings in the United Kingdom.

The nasal spray is being offered in the United Kingdom through the company’s subsidiary company Pasithea Clinics. The nasal spray in question is meant for treating adults who may be suffering from depression and have not found relief from other forms of treatment.

The company revealed that the spray is not only effective but it is also safe to use. Depression is a worldwide problem and is regarded as one of the major reasons behind long-term disabilities. Many patients suffer from any lack of treatment options and the nasal spray gives them an effective option. The excitement among investors with regard to the product is understandable.

3 Biofrontera (NASDAQ:BFRI)

Last but certainly not least, it is the Biofrontera stock that has grabbed headlines in recent days after having emerged as a major point of focus among investors. Over the course of the past week, the Biofrontera stock has rocketed upwards and managed to clock gains of as much as 175% during the period.

The rally in the Biofrontera stock has come about after a bullish projection from the analyst Jonathan Aschoff of Roth Capital. The analyst started covering the stock last week and set the target price at $20 a share. Aschoff noted that the stock could end up delivering considerable returns primarily due to the sales plans that have been put in place by Biofrontera for the United States market.

read more
Quick Takes: Market Research on VLON, ALF and BTB

Quick Takes: Market Research on VLON, ALF and BTB

Nov 24, 2021

Company Snapshot

Company Name: Vallon Pharmaceuticals, Inc. 

Ticker: (VLON)

Exchange: NASDAQ

Website: www.vallon-pharma.com

Company Summary:

Vallon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, headquartered in Philadelphia, PA. The Company is focused on the development of new medications to help patients with CNS disorders. The Company’s lead investigational product candidate, ADAIR, is a novel abuse deterrent formulation of amphetamine immediate release being developed for the treatment of ADHD and narcolepsy.

Why did it go up over 100%?

Vallon Pharmaceuticals, Inc. reported its financial results for the quarter ended September 30, 2021.

Also announced, ADAIR is the Company’s proprietary abuse-deterrent formulation of immediate-release dextroamphetamine currently in development for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. ADAIR is being developed leveraging the de-risked 505(b)(2) regulatory pathway and is currently being evaluated in the SEAL study, a pivotal intranasal abuse study. If approved, ADAIR has the potential to address the growing Adderall® segment of the ~$9 billion US ADHD market.

Technical Analysis:

Anytime there is a big spike in price action there normally is a pull back, the whole adage, what goes up must comes down takes over. In the first chart you can see an obvious spike of over 100% with a pull back. How far will it pull back, that is speculation but right now we know it is pulling back. In the second chart you can see the pull back/sell off is still supported around $6.50 which is promising for the future. Make sure it stays above $6.10. 

Company Snapshot

Company Name: Bit Brother Limited 

Ticker: (BTB)

Exchange: NASDAQ

Website: https://bitbrothers.in/

Company Summary:

A team of experienced data scientists, data engineers, developers and designers, ready to help you build your web and mobile application

Why did it go up over 100%?

Bit Brother Limited share price is up 86% in the last month. But has been plagued with 5 years of declines. So why has it started to bounce back? Big News? No. The only reason we see for the increase is a modest increase in revenue which means this stock should not be increasing share price as much as it has in this month based on the modest increases in revenue. Be aware!

Technical Analysis:

Bit Brother Limited share price is in worse shape than it was before the massive run of over 150% with nominal news. We see this everyday in the market, stocks get over bought and then without fail, the stocks come plumitting. This is no different and we are not optimistic in the short term with Bit Brother.

Company Snapshot

Company Name: Alfi, Inc. 

Ticker: (ALF)

Exchange: NASDAQ

Website: https://www.getalfi.com/about-us/

Company Summary:

Alfi, Inc. engages in creating interactive digital out-of-home advertising experiences. Alfi utilizes artificial intelligence and computer vision to better serve ads to people. Alfi’s proprietary Ai algorithm understands small facial cues and perceptual details that make potential customers a good candidate for a particular product.

Why did it go up over 100%?

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alfi, Inc. (“Alfi” or “the Company”) (NASDAQ: ALF) for violations of the securities laws.

Technical Analysis

Stay away, well, because it is a garbage chart with no foreseeable rebound. Moreover, it is very strange that Alfi ran after the news, nothing makes sense with this stock!

read more
3 STOCKS, 3 Stories and 3 Takeaways: ISPC, ASTR & PRVB!

3 STOCKS, 3 Stories and 3 Takeaways: ISPC, ASTR & PRVB!

Nov 23, 2021

A tale of three stocks, a tale as old as time: ISPC, ASTR & PRVB

Company Snapshot

Company Name: iSpecimen

Ticker: ISPC

Exchange: NASDAQ

Website: www.ispecimen.com

Industry  Medical

Company Summary:

iSpecimen offers an online marketplace for human biospecimens, connecting life scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. 

Why did it go up over 100%?

iSpecimen announced yesterday that it has been contracted to support new advanced research on COVID-19 seeking insights on its transmissibility, variants, outcomes, and testing validity among multiple population segments. In the last ten months, the company has partnered with multiple research and health care organizations on a range of diverse projects requiring a variety of COVID-19 samples, including nasal swabs, saliva, and blood products.

1 Day Chart 

Technical Analysis

There was a mad rush to buy this stock after the news that iSpecimen had been contracted to support new advanced research on COVID-19 seeking insights on its transmissibility, variants, outcomes, and testing validity among multiple population segments. Anything related to Covid is going crazy simply because it has impacted our lives so significantly that we are overly interested in solutions to this worldwide pandemic. 

So, my technical analysis of this Covid stock is, it was overbought hence the pull back after the premarket buy up. The correction was significant at $11.64 to an intraday low of $8.12 accounting for a 30% retrace. It broke out of the bullish trend at the end of the day, but it could be a head fake. Be careful and make sure to get a solid confirmation before thinking about this purchase. 

Company Snapshot

Company Name: Astra Space, Inc.

Ticker: ASTR

Exchange: NASDAQ

Website: www.astra.com 

Company Summary:

Astra’s mission is to improve life on Earth from space by creating a healthier and more connected planet. Today, Astra offers the one of the lowest cost-per-launch dedicated orbital launch service of any operational launch provider in the world. Astra completed its first commercial orbital launch in November 2021, making it one of the fastest U.S. company in history to reach this milestone. Astra is based in Alameda, California, and was founded in 2016. 

Why did it go up over 50%?

Astra Space successfully completed its first commercial orbital launch for the United States Space Force late Friday night, November 19, 2021, PST. The launch, STP-27AD2, was conducted from Astra’s Kodiak Spaceport, located at the Pacific Spaceport Complex in Kodiak, Alaska. 

1 Month Chart 

5 Day Chart 

Technical Analysis

Again, this is a very popular subject since Tesla, Elon Musk and Space X became the talk of the world after reaching space! So, what does the market do upon the big news, they buy this stock up in a mad frenzy in response. Our advice is the same as iSpecimen, wait for a solid confirmation of a breakout. We are looking for a consolidation and a breakout, keep an eye on it!

Company Snapshot

Company Name: Provention Bio

Ticker: PRVB

Exchange: Nasdaq

Website: www.proventionbio.com

Industry BioMedical

Company Summary:

Provention Bio, Inc. is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated disease. The Company’s pipeline includes clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in autoimmune diseases, including type 1 diabetes, celiac disease and lupus.

Why did it go up over 15%?

Provention Bio had a Type A meeting with the FDA to discuss the population pharmacokinetic (popPK) model to be used for the purpose of planned commercial and clinical drug product comparison. In preliminary meeting comments, the FDA approved the Company proceeding to populate the popPK model with data collected from patients receiving therapeutic doses of teplizumab in a pharmacokinetic/pharmacodynamic (PK/PD) substudy of the ongoing PROTECT Phase 3 trial in newly diagnosed type 1 diabetes (T1D) patients (Commercial Product N~30 patients, Clinical Drug Product N~130 patients).

1 Day Chart 

Technical Analysis

We think this is a reasonable market reaction to the news, it wasn’t over-purchased, it was just right! Now of course, reactions work in both directions, up and down. So even though it was a proper spike, why did it pull back, human reaction! It spikes and starts retracing and the market gets afraid. 

Summary on ISPC, ASTRA & PRVB

3 stories and three takeaways! A tale of three stocks, a tale that has been told since the inception of the stock exchanges. 

  1. Takeaway 1: What goes up (fast) must go down  – premarket huge spikes are normally a dangerous play. If you really like the stock, wait, let it pull back from the over buying and make an extra 10-50% by being patient!
  2. Takeaway 2: Traders normally over react – in a world where the all mighty dollar is the true definition of happiness and success, combined with our optimistic nature, breads an environment for the “get rich fast” idea. We all want desperately to “hit it big” that’s why Vegas is what it is. 
  3. Takeaway 3: Carefully curated news properly placed creates a massive amount of interest specially when written properly.

Happy trading and REMEMBER, never try to catch a falling safe! Let it crash to the ground and walk over and pick up the money!

read more
NanoVibronix Inc (NASDAQ:NAOV) Is About To Hit $3: A Good Buy Now?

NanoVibronix Inc (NASDAQ:NAOV) Is About To Hit $3: A Good Buy Now?

Jul 29, 2021

If you are currently hunting for a big mover in the market then it might be time to take a closer look at the NanoVibronix Inc (NASDAQ:NAOV) stock. It has managed to emerge as one of the biggest gainers over the past week or so and has gone up by as much as 35% this morning.

The latest rally has taken the gains made by the NanoVibronix stock over the past week to as much as 200%. The company is involved in the medical device industry and best known for producing PainShield and UroShield Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices. The stock is on the move because recently the company announced that it successfully completed the first order that had been placed for its new age pain management device PainShield Plus.

It was a major development for the company and the reaction in the markets to that update was perfectly understandable. In this regard, there is another thing that needs to be factored in by investors. NanoVibronix also revealed that the revenues generated from the first sale of PainShield Plus units are going to be recognised in the third quarter of 2021.

In addition to that, the product is certainly an upgrade on the previous PainShield device. It covers twice the surface area as compared to the earlier version of the product. On the other hand, NanoVibronix can also realize higher margins when selling this product and that is possibly another reason behind the optimism among investors.

read more
Infinity Pharmaceuticals (NASDAQ:INFI) Stock Bounces Back After Yesterday’s Fall

Infinity Pharmaceuticals (NASDAQ:INFI) Stock Bounces Back After Yesterday’s Fall

Jul 28, 2021

On Tuesday, the Infinity Pharmaceuticals (NASDAQ:INFI) stock had suffered from a heavy selloff and had gone down by as much as 61%. However, this morning it is a different stock for the company as the stock has recovered strongly and gone up by as much as 38%.

There has been no fresh news about the company this morning and hence, the rally in the stock could be related to the announcement made by the company yesterday. On Tuesday, Infinity provided updates with regards to the MARIO-275 randomized placebo-based Phase 2 study into its flagship product eganelisib. In this study, the product, which is meant for reversing the immune suppression in cancer patients and spark anti-tumor activity, was administered to the patients in combination with nivolumab.

As per the data from the company that was released on Tuesday, the median overall survival figure when administered with this combination shot up to as much as 15.9 months. In comparison, patients who had only been administered with nivolumab had a median survival rate of 7.9 months. Hence, it is clear to see why the latest data released by Infinity Pharmaceuticals may have come as a source of considerable excitement for many investors.

The data suggests that if eganelisib is added to the standard medication for cancer patients, then there is a high chance of progression-free survival for patients. Hence, it is now going to be interesting to see if the stock can continue to add to its gains today in light of the positive data.

read more
Relief Therapeutics Holding AG (RLFTF) Stock Makes an Interesting Move: Are You Excited?

Relief Therapeutics Holding AG (RLFTF) Stock Makes an Interesting Move: Are You Excited?

Jul 26, 2021

This morning many investors are going to be looking into stocks that recorded considerable gains last week and by that token, it is likely that the Relief Therapeutics Holding AG (OTCMKTS:RLFTF) stock is going to be one of those. The stock recorded gains of 25.50% this past Friday and ended the week with cumulative gains of as much as 57%.

Hence, it might be a good idea to actually keep an eye on the Relief stock this morning. The rally in the stock was brought about by a press release from the company’s collaboration partner NRx Pharmaceuticals last week. In the press release, the company provided information about a key milestone regarding aviptadil, the product on which the two companies are working.

NRx revealed that a commercial formulation of aviptadil that could be put to intravenous use had been validated. That is a major development since the company will now start preparing for industrial-scale manufacturing of the product. It was also noted that the aviptadil that is going to be commercially manufactured will also have the stability of a year or more as long as it is stored in ideal conditions.

On the other hand, NRx has also managed to boost its manufacturing capacity and is in a position to boost the manufacturing lot size of aviptadil by 30 to 50 times. It was a major development and it was no surprise that the Relief Therapeutics stock moved in such a big way. It remains to be seen if the stock can continue to add to its gains today.

read more